Diranersen cut Alzheimer’s cognitive decline by 54% in a major trial
Patients given low-dose diranersen injections had 54% less decline on a memory and thinking test over almost two years, according to The Telegraph. The drug uses gene-silencing technology to reduce production of tau, and is given by lumbar puncture; the result needs confirmation in a phase three trial.
Bottom line — UK recruitment for the next diranersen trial is expected to start in spring.
Go deeper 6
-
Alzheimer’s Society research and innovation director Richard Oakley said the results were encouraging, but said the findings need confirmation in phase three.
-
The CELIA trial results were announced at a clinical trials conference in Boston, according to The Independent.
-
Diranersen targets tau by blocking RNA messages that tell brain cells to produce the protein, The Independent reported.
-
The treatment is given by lumbar puncture into fluid around the spinal cord, The Independent reported.
-
The Independent reported that the treatment is given twice a year.
-
British patients are asking to join the next trial, with UK recruitment expected to begin in spring, The Telegraph reported.